Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia

American Journal of Psychiatry

Volumn 154, Issue 1, 1997, Pages 56-63

  Busatto, Geraldo F ^a   Pilowsky, Lyn S ^a   Costa, Durval C ^a   Ell, Peter J ^a   David, Athony S ^a   Lucey, James V ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR; IOMAZENIL;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; GABAERGIC TRANSMISSION; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE DIAGNOSIS; RATING SCALE; RECEPTOR BINDING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; SYMPTOMATOLOGY;

EID: 0031013988     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.1.56     Document Type: Article

References (54)

1. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980; 137:1518-1522
2. Crow TJ: Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280:66-68
3. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
4. Kisvarday ZF, Gulyas A, Beroukas D, North JB, Chubb IW, Somogyi P: Synapses, axonal and dendritic patterns of GABA-immunoreactive neurons in human cerebral cortex. Brain 1990; 113:793-812
5. Roberts GW: Schizophrenia: a neuropathological perspective. Br J Psychiatry 1991; 158:8-17
6. Benes FM: Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophr Bull 1993; 19:537-549
7. Reynolds GP, Czudek C, Andrews HB: Deficit and hemispheric asymmetry of GABA reuptake sites in the hippocampus in schizophrenia. Biol Psychiatry 1990; 27:1038-1044
8. Scheel-Kruger J: Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand Suppl 1986; 107:1-54
9. Stevens J, Wilson K, Foote W: GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia 1974; 39:105-119
10. Wood PL: Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther 1982; 222:674-679
11. van Kammen DP: γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 1977; 134: 138-143; correction, 134:463-464
12. van Kammen DP: γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 1977; 134: 138-143; correction, 134:463-464
13. Bird ED, Barnes J, Iversen LL, Spokes EG, Mackay AVP, Shepherd M: Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 1977; 2:1157-1159
14. Perry TL, Buchanan J, Kish SJ, Hansen S: Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1979; 1:237-239
15. Spokes EGS, Garrett NJ, Rossor MN, Iversen LL: Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J Neurol Sci 1980; 48:303-313
16. Simpson MDC, Slater P, Deakin JTW, Royston MC, Skan WJ: Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989; 107:211-215
17. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992; 12:924-929
18. Perry TL, Hansen S, Jones K: Schizophrenia, tardive dyskinesia, and brain GABA. Biol Psychiatry 1989; 25:200-206
19. Beer HF, Blauenstein PA, Hasler PH, Delalo EB, Riccabona G, Bangerl I, Hunkeler RW, Pieri L, Richards JG, Schubiger PA: In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 1990; 31:1007-1014
20. Woods SW, Seibyl JP, Goddard AW, Dey HM, Zoghbi SS, Germine M, Baldwin RM, Smith EO, Charney DS, Heninger GR, Hoffer PB, Innis RB: Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects. Psychiatry Res Neuroimaging 1992; 45:67-77
21. 123I]iomazenil SPECT: technical and interobserver variability. Nucl Med Commun 1993; 14:634-643
22. 123I]Iomazenil single photon emission tomography (SPET). Eur J Nucl Med 1995; 22:12-16
23. Annett M: A classification of hand preference by association analysis. Br J Psychol 1970; 61:303-321
24. Lukoff D, Liberman RP, Nuechterlein KH: Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull 1986; 578-602
25. Andreasen NC: Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39:784-788
26. Kouris K, Jarritt PH, Costa DC, Ell PJ: Physical assessment of the GE/CGR Neurocam and comparison with a single rotating gamma-camera. Eur J Nucl Med 1992; 19:236-242
27. Damasio H, Damasio AR: Lesion Analysis in Neuropsychology. New York, Oxford University Press, 1989
28. Ebmeier KP, Dougall NJ, Austin MPV, Murray CL, Curran SM, O'Carroll R, Moffoot APR, Hannan J, Goodwin GM: The split-dose technique for the study of psychological activation with the cerebral blood flow marker exametazine and single photon emission computed tomography (SPECT): reproducibility and rater reliability. Int J Methods in Psychiatr Res 1991; 1:27-38
29. Abadie P, Baron JC, Bisserbe JC, Boulenger P, Rioux JM, Travere L, Barre MC, Petit-Taboue MC, Zarifian E: Central benzodiazepine receptors in human brain: estimation of regional Bmax and Kd values with positron emission tomography. Eur J Pharmacol 1992; 213:107-115
30. Farde L, Eriksson L, Blomquist G, Halldin C: Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9:696-708
31. Knable MB, Jones DW, Coppola R, Hyde TM, Lee KS, Gorey J, Weinberger DR: Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995; 36:1216-1225
32. Abi-Dargham A, Gandelman M, Zoghbi SS, Laruelle M, Baldwin RM, Randall P, Charney DS, Hoffer PB, Innis RB: Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. J Nucl Med 1995; 36: 167-175
33. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates, II: equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 1994; 14:453-465
34. Vincent SL, Adamec E, Sorensen I, Benes FM: The effects of chronic haloperidol administration on GABA-immunoreactive axon terminals in rat medial prefrontal cortex. Synapse 1994; 17:26-35
35. 3H]Muscimol binding sites in autopsied brains of chronic schizophrenics. Life Sci 1987; 40:259-266
36. Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Toru M: Benzodiazepine receptors increase in post-mortem brain of schizophrenics. Eur Arch Psychiatry Neurol Sci 1989; 239:71-78
37. Reynolds GP, Stroud D: Hippocampal benzodiazepine receptors in schizophrenia. J Neural Transm Gen Sect 1993; 93:151-155
38. 3H)-flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychosis? Neurochem Res 1993; 18:219-223
39. Sieghart W: Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci 1994; 19:24-29
40. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160:179-186
41. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM: Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 1993; 11:47-54
42. Abi-Dargham A, Krystal J, Laruelle M, D'Souza D, Zoghbi SS, Brenner L, Gill R, Sernyak M, Baldwin RM, Zubal G, Hoffer PB, Charney DS, Innis RB: SPECT imaging of the benzodiazepine receptor in schizophrenics and healthy subjects (abstract). Schizophr Res 1995; 15:75
43. Waddington JL, Cross AJ: Denervation supersensitivity in the striatonigral GABA pathway. Nature 1978; 276:618-619
44. 3H]muscimol in the barrel field of mice after peripheral denervation: transient and long-lasting effects. Exp Brain Res 1994; 100:39-46
45. Falkai P, Bogerts B: Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 1986; 236:154-161
46. Benes FM, Sorensen I, Bird ED: Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr Bull 1991; 17:597-608
47. van Hoesen GW: The parahippocampal gyrus: new observations regarding its cortical connections in the monkey. Trends Neurosci 1982; 5:345-350
48. Schmajuk NA, DiCarlo JJ: A hippocampal theory of schizophrenia. Behavioral Brain Sci 1991; 14:47-49
49. Braff DL: Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 1993; 19:233-259
50. Frith CD: Consciousness, information processing, and schizophrenia. Br J Psychiatry 1979; 134:225-235
51. Hemsley DR: An experimental psychological model for schizophrenia, in Search for the Causes of Schizophrenia. Edited by Hafner H, Gattaz WF, Janzarik W. Heidelberg, Germany, Springer-Verlag, 1987, pp 179-188
52. Wolkowitz OM, Pickar D: Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148:714-726
53. Haefely W, Martin JR, Schoch P: Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990; 11:452-456
54. Delini-Stula A, Berdah-Tordjman D: Benzodiazepines and GABA hypothesis of schizophrenia. J Psychopharmacol 1995; 9:57-63